| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | ||
| Market Cap | 58.91 Cr. | |
| Enterprise Value(EV) | 88.80 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.14 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 18.68 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 28.96 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 33.95 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 1.18 | Calculated using Price: 40.00 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.49 Cr. | 14,876,520 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain. It is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of custom research, In-vitro and In-vivo toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities. The Custom Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins. In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists. Vivo Bio Tech has obtained permission from the Govt. of India for developing Biotech Sector Specific 'Special Economic Zone' at its site (39 acres) in Pregnapur, Gajwel Mandal, Medak District, Andhra Pradesh.The Vivo Bio Tech SEZ is located adjacent to Karimnagar highway road (approx 16 km from ICICI Knowledge Park and SP Biotech Park). The site is approximately 53km from Secunderabad Railway Station and around 90km from the new airport (Shamshabad). |
||
Company Profile
Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain.
It is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of custom research, In-vitro and In-vivo toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities.
The Custom Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins.
In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists.
Vivo Bio Tech has obtained permission from the Govt. of India for developing Biotech Sector Specific 'Special Economic Zone' at its site (39 acres) in Pregnapur, Gajwel Mandal, Medak District, Andhra Pradesh.The Vivo Bio Tech SEZ is located adjacent to Karimnagar highway road (approx 16 km from ICICI Knowledge Park and SP Biotech Park). The site is approximately 53km from Secunderabad Railway Station and around 90km from the new airport (Shamshabad).
| 1 Day |
|
+0.76% |
| 1 Week |
|
+4.71% |
| 1 Month |
|
-13.42% |
| 3 Month |
|
|
| 6 Month |
|
-35.85% |
| 1 Year |
|
-40.48% |
| 2 Year |
|
+42.86% |
| 5 Year |
|
-58.76% |
| 10 Year |
|
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 5.91 | 3.52 | 5.25 | 9.48 | 22.17 | 21.01 | 10.21 | 14.85 | 15.36 | |
| Return on Capital Employed (%) | 7.83 | 7.95 | 4.72 | 5.96 | 12.39 | 15.18 | 9.58 | 13.85 | 18.81 | |
| Return on Assets (%) | 0.83 | 0.75 | 1.14 | 2.09 | 5.17 | 5.64 | 3.92 | 7.58 | 8.02 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 8 | 9 | 9 | 10 | 13 | 19 | 27 | 33 | 43 | 46 | |
| Non Curr. Liab. | 5 | 5 | 4 | 15 | 22 | 15 | 9 | 9 | 15 | 16 | |
| Curr. Liab. | 26 | 26 | 28 | 20 | 17 | 25 | 19 | 21 | 22 | 20 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 39 | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 82 | |
| Non Curr. Assets | 21 | 21 | 20 | 24 | 32 | 32 | 30 | 35 | 52 | 50 | |
| Curr. Assets | 18 | 19 | 22 | 22 | 20 | 28 | 25 | 27 | 27 | 32 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total Assets | 39 | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 82 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 14 | 16 | 18 | 29 | 34 | 47 | 56 | 55 | 52 | 52 | |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 15 | 17 | 19 | 29 | 35 | 47 | 56 | 55 | 52 | 53 | |
| Total Expenditure | -12 | -14 | -15 | -25 | -27 | -36 | -46 | -43 | -34 | -34 | |
| PBIDT | 3 | 3 | 4 | 5 | 8 | 11 | 10 | 13 | 18 | 19 | |
| Interest | -1 | 0 | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | |
| Depreciation | -2 | -2 | -3 | -3 | -4 | -5 | -5 | -5 | -6 | -7 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -3 | -4 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 3 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 0 | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 3 | |
| Adjusted EPS | 0 | 0 | 0 | 1 | 3 | 3 | 2 | 3 | 4 | 2 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 5 | 2 | 3 | 2 | 9 | -6 | 11 | -1 | 9 | 14 | |
| Cash Fr. Inv. | -5 | 25 | -1 | -2 | -7 | -12 | -5 | -4 | -10 | -23 | |
| Cash Fr. Finan. | 0 | -19 | 0 | -1 | 0 | 7 | -3 | 1 | 2 | 9 | |
| Net Change | 0 | 8 | 1 | -1 | 1 | -11 | 3 | -4 | 0 | 0 | |
| Cash & Cash Eqvt | 2 | 10 | 11 | 11 | 12 | 1 | 4 | 1 | 1 | 1 |
|
Mon, 16 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance Report for the year ended 31st March 2022 |
|
Mon, 09 May 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Iragavarapu Constructions Pvt Ltd |
|
Mon, 09 May 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Shri Shri Resorts Pvt Ltd |
| Wed, 18 May 2022 |
Close Within 52 Week Low Zone
|
High Decrease 1 Month
|
High Decrease 6 Months
|
High Decrease 1 Year
|
| Tue, 17 May 2022 |
Opening at High
|
Equities
M.F.
Sectors